Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). The business earned $23.57 million during the quarter, compared to the consensus estimate of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company's quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) EPS. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Momenta Pharmaceuticals.

9 equities research analysts have issued 1 year target prices for Momenta Pharmaceuticals' stock. Their predictions range from $6.00 to $18.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $14.44 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Momenta’s sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. We are pleased with the company’s efforts to develop biosimilars given the potential in the market with recent approvals. In addition, a potential approval of M923 will boost investor confidence. The company has collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates. However, the ANDA approval for Glatopa 40mg is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months. The recent FDA approval of Mylan's generic version of Copaxone 40mg led to significant plunge in the share price." (10/11/2017)
• 2. Cowen and Company analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
• 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
• 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

Some companies that are related to Momenta Pharmaceuticals include Immunomedics (IMMU), Spectrum Pharmaceuticals (SPPI), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Genus plc (GNS), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Albany Molecular Research (AMRI), Abeona Therapeutics (ABEO), Heron Therapeutics (HRTX) and CRISPR THERAPTC (CRSP).

Momenta Pharmaceuticals' management team includes the folowing people:

• Craig A. Wheeler, President, Chief Executive Officer, Director
• Scott M. Storer, Chief Financial Officer, Senior Vice President
• Ganesh Venkataraman Kaundinya Ph.D., Chief Operating Officer, Chief Scientific Officer
• Bruce A. Leicher, Senior Vice President, General Counsel, Secretary
• Bruce L. Downey, Independent Director
• Corey N. Fishman, Independent Director
• Georges Gemayel Ph.D., Independent Director
• Steven C. Gilman Ph.D., Independent Director
• Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director

Momenta Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.13%) and Eqis Capital Management Inc. (0.03%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Momenta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $14.05.